213 related articles for article (PubMed ID: 22139971)
1. Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.
Andersen NF; Vogel U; Klausen TW; Gimsing P; Gregersen H; Abildgaard N; Vangsted AJ
Int J Cancer; 2012 Sep; 131(5):E636-42. PubMed ID: 22139971
[TBL] [Abstract][Full Text] [Related]
2. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Vangsted AJ; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Nexø BA; Vogel U
Ann Hematol; 2011 Oct; 90(10):1173-81. PubMed ID: 21347685
[TBL] [Abstract][Full Text] [Related]
3. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H
Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients.
Kim DH; Lee NY; Lee MH; Sohn SK; Do YR; Park JY
Br J Haematol; 2008 Jan; 140(1):71-9. PubMed ID: 17983459
[TBL] [Abstract][Full Text] [Related]
5. Association of vascular endothelial growth factor (VEGF) gene polymorphism and increased serum VEGF concentration with pancreatic adenocarcinoma.
Sivaprasad S; Govardhan B; Harithakrishna R; Venkat Rao G; Pradeep R; Kunal B; Ramakrishna N; Anuradha S; Reddy DN
Pancreatology; 2013; 13(3):267-72. PubMed ID: 23719599
[TBL] [Abstract][Full Text] [Related]
6. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
[TBL] [Abstract][Full Text] [Related]
7. Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.
Cibeira MT; de Larrea CF; Navarro A; Díaz T; Fuster D; Tovar N; Rosiñol L; Monzó M; Bladé J
Leuk Res; 2011 Sep; 35(9):1178-83. PubMed ID: 21435719
[TBL] [Abstract][Full Text] [Related]
8. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.
Almasi M; Sevcikova S; Slaby O; Kaisarova P; Maisnar V; Penka M; Pika T; Pour L; Radocha J; Scudla V; Svachova H; Hajek R
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):414-20. PubMed ID: 21859556
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease.
Kim DH; Lee NY; Lee MH; Sohn SK
Biol Blood Marrow Transplant; 2008 Dec; 14(12):1408-16. PubMed ID: 19041064
[TBL] [Abstract][Full Text] [Related]
10. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
[TBL] [Abstract][Full Text] [Related]
11. The relation of vascular endothelial growth factor (VEGF) gene polymorphisms on VEGF levels and the risk of vasoocclusive crisis in sickle cell disease.
Al-Habboubi HH; Mahdi N; Abu-Hijleh TM; Abu-Hijleh FM; Sater MS; Almawi WY
Eur J Haematol; 2012 Nov; 89(5):403-9. PubMed ID: 22925497
[TBL] [Abstract][Full Text] [Related]
12. Relationship of common vascular endothelial growth factor polymorphisms and haplotypes with the risk of cervical cancer in Tunisians.
Zidi S; Stayoussef M; Gazouani E; Mezlini A; Yacoubi-Loueslati B; Almawi WY
Cytokine; 2015 Jul; 74(1):108-12. PubMed ID: 25541433
[TBL] [Abstract][Full Text] [Related]
13. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
Kasamatsu T; Saitoh T; Ino R; Gotoh N; Mitsui T; Shimizu H; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Murakami H
Hematol Oncol; 2017 Dec; 35(4):711-718. PubMed ID: 27405747
[TBL] [Abstract][Full Text] [Related]
15. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Rajkumar SV; Witzig TE
Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
[TBL] [Abstract][Full Text] [Related]
16. Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage.
Almawi WY; Saldanha FL; Mahmood NA; Al-Zaman I; Sater MS; Mustafa FE
Hum Reprod; 2013 Oct; 28(10):2628-35. PubMed ID: 23900206
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
Vacca A; Scavelli C; Montefusco V; Di Pietro G; Neri A; Mattioli M; Bicciato S; Nico B; Ribatti D; Dammacco F; Corradini P
J Clin Oncol; 2005 Aug; 23(23):5334-46. PubMed ID: 15939924
[TBL] [Abstract][Full Text] [Related]
18. Contribution of VEGF polymorphisms to variation in VEGF serum levels in a healthy population.
Al-Habboubi HH; Sater MS; Almawi AW; Al-Khateeb GM; Almawi WY
Eur Cytokine Netw; 2011 Sep; 22(3):154-8. PubMed ID: 21982816
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.
Sissung TM; Peer CJ; Korde N; Mailankody S; Kazandjian D; Venzon DJ; Landgren O; Figg WD
Cancer Chemother Pharmacol; 2017 Jul; 80(1):217-221. PubMed ID: 28488026
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia.
Lozano-Santos C; Martinez-Velasquez J; Fernandez-Cuevas B; Polo N; Navarro B; Millan I; Garcia JM; Collado R; Sanchez-Godoy P; Carbonell F; Garcia-Vela JA; Garcia-Marco JA; Gomez-Lozano N
PLoS One; 2014; 9(6):e101063. PubMed ID: 24971577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
